AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02616601
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream, placebo. Has no active ingredient.
Trial: NCT03123185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet and solution formulation
Trial: NCT03252340
Drug: ADSTEM Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.
Trial: NCT03851731
Drug: Naltrexol
RxNorm normalized name: 6-beta-naltrexol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal spray
Trial: NCT01905215
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
Trial: NCT04041791
Drug: Gentamicin Sulfate
RxNorm normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin is an aminoglycoside antibiotic.
Trial: NCT01784419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects were randomized to ivacaftor 150 mg by mouth twice a day for 14 days followed by placebo for 14 days, or vice versa. Randomization was based on a computer-generated schedule produced by the research pharmacy, which was concealed from study personnel until study completion. Ivacaftor was purchased at full retail cost and encapsulated with sucrose to match the sucrose-filled placebo capsules. Prior to beginning study drug, there was a 2-week run-in period to ensure clinical stability, assessed by modified Fuchs criteria and pulmonary function. There was a washout period of a minimum of 14 days between study drug cycles to account for carryover effect. The washout period was extended to 6 weeks for subjects on alternating cycles of inhaled antibiotics to coordinate the study drug cycle with the inhaled antibiotic cycle.
Trial: NCT02280083
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03597217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01757236
Drug: CLINDAMYCIN
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01757236
Drug: FLUOROQUINOLONE
RxNorm normalized name: Fluoroquinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00188071
Drug: ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00188071
Drug: ketoprofen + paracetamol
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00364273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo administered using DISKUS inhaler.
Trial: NCT00641381
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/kg on day -2 prior to stem cell reinfusion
Trial: NCT03514511
Drug: LEO 138559
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 138559 is a compound in development at LEO Pharma A/S
Trial: NCT03514511
Drug: LEO 138559 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEO 138559 placebo
Trial: NCT02251548
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV alkylator chemotherapy agent
Trial: NCT03555851
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
Trial: NCT01558869
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
Trial: NCT03471039
Drug: PACAP27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of PACAP27 over 20 minutes.
Trial: NCT01230775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/
Trial: NCT03869684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo manufactured to mimic MT-0814
Trial: NCT02873520
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Trial: NCT00931346
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emtricitabine/tenofovir disoproxil fumarate
Trial: NCT00931346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00415142
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration (capsules)
Trial: NCT01856764
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast formulation vehicle
Trial: NCT01358071
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
Trial: NCT01358071
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m² iv every 3 weeks for a maximum of 8 cycles
Trial: NCT04224545
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo started a day before surgery, 2, 3, 4, 5 days after surgery.
Trial: NCT02905799
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
Trial: NCT04295109
Drug: the drug of intravenous patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At present, opioids are most widely used in postoperative analgesia. This study aims to use different opioid receptor agonists---fentanyl, oxycodone and butorphanol for analgesia after laparoscopic hysterectomy.Compare the recovery of gastrointestinal function after operation.
Trial: NCT00789568
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg/kg and 100 mg/kg
Trial: NCT00654446
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02656095
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
Trial: NCT00654446
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02514473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04029688
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m\^2) as an intravenous (IV) infusion.
Trial: NCT00142844
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04304547
Drug: CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet
Trial: NCT04590326
Drug: REGN5668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN5668 will be administered by once weekly intravenous (IV) infusion.
Trial: NCT04304547
Drug: CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once
Trial: NCT03452111
Drug: Nestorone + Testosterone Combination Gel
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
Trial: NCT04304547
Drug: CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet
Trial: NCT03967977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab placebo to match
Trial: NCT04424511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.
Trial: NCT04424511
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.
Trial: NCT01851694
Drug: GIP
RxNorm normalized name: GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject in this arm will receive GIP infusion and placebo during a GPA test.
Trial: NCT03210272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04243616
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
Trial: NCT04243616
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
Trial: NCT00677053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
Trial: NCT03157505
Drug: Purethal Birch immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purethal birch was administered as perennial therapy: 24 months
Trial: NCT00609362
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One encapsulated placebo pill a day for 14 weeks
Trial: NCT00065130
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00256880
Drug: GW786034
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01332565
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg tablet
Trial: NCT02128360
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01525901
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution will be administered for three months subcutaneously.
Trial: NCT00195845
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00298168
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
Trial: NCT03573648
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)
Trial: NCT02711579
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02711579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00845481
Drug: Betnovat® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application 6 days a week for 3 weeks
Trial: NCT00845481
Drug: Daivobet® ointment vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application 6 days a week for 3 weeks
Trial: NCT04595786
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline was prepared in a 50ml syringe for intravenous pump
Trial: NCT00150644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablet, oral Daily for 12 weeks
Trial: NCT03232138
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients
Trial: NCT01804634
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: preparative regimen
Trial: NCT02914535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once daily
Trial: NCT02656212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill, taken orally, one pill/day in the morning
Trial: NCT03250013
Drug: ADHD medications
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03742908
Drug: Cefazolin/clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local implant immersion and/or breast pocket irrigation
Trial: NCT01995006
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen tablets (500mg): 500 mg BID during 7 days
Trial: NCT00908583
Drug: plasmapheresis
RxNorm normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
Trial: NCT00984568
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
Trial: NCT00984568
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
Trial: NCT01025492
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet po daily
Trial: NCT01726452
Drug: 5 Flourouracil/ Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
Trial: NCT02643394
Drug: Oral Acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
Trial: NCT01726452
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m², day 1 of each cycle (i.e. every 14 days).
Trial: NCT03422822
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
Trial: NCT02643394
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
Trial: NCT02964507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT00891709
Drug: LEO 29102
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-in-man. Healthy volunteers
Trial: NCT02362594
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution administered IV on Day 1 of each 21-day cycle
Trial: NCT01582854
Drug: Actovegin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin solution for infusion and Actovegin tablets
Trial: NCT01582854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
Trial: NCT02391805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
Trial: NCT02391805
Drug: RO6864018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
Trial: NCT01225315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally twice daily
Trial: NCT01858129
Drug: Experimental group: Budicort by Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Budicort twice daily
Trial: NCT01858129
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02684669
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT04048278
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
Trial: NCT03992339
Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
Trial: NCT00287235
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01262352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral use, twice daily every 12 hours (q12h)
Trial: NCT02235727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02036554
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Trial: NCT00035347
Drug: IV azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg once daily
Trial: NCT00035347
Drug: oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 x 250 mg once daily
Trial: NCT01721980
Drug: GLPG0974
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01721980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01390220
Drug: USL261
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01390220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00450658
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 800mg orally 3 times daily for 24 weeks
Trial: NCT04318041
Drug: Artrodar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein (Artrodar):~D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal